Skip to main content
Equibles
NASC logo

NASC · Can B Corp · Metrics

Track NASC — free

Use NASC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NASC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Nov 19, 2024

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt as to the Company's ability to continue as a going concern.”
View the 10-Q filed Nov 19, 2024
Market Cap
$758,419
Shares
75.84M
Volume · Nov 12 20K Avg daily vol (3M) 54.48K

NASC metrics

59 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.01
Market cap
$758,419

Price action

23 metrics
Price change (1W)
+15.3%
Price change (30D)
-18.3%
Price change (3M)
+5.4%
Price change (6M)
-24.6%
Price change (YTD)
-38.8%
Price change (1Y)
-45.6%
Trailing year
Price change (5Y)
—
52-week high
$0.04
52-week low
$0.01
Change from 52-week high
-72.0%
Change from 52-week low
+44.1%
Annualized volatility
262.0%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.3
RSI (14D)
46.3
Price vs SMA 50
-10.3%
Price vs SMA 200
-36.7%
Avg volume (3M)
54,909
Relative volume
0.6
Average dollar volume
$612

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
75.84M

Valuation

12 metrics
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 714.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 136.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
3.1
reciprocal yield 32.5%
Earnings yield
-1,748.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
4.6×
reciprocal yield 21.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-33.2%
Operating margin
-1,035.9%
Trailing 12 months
Net margin
-1,282.8%
Gross profit (TTM)
−$343,304
Operating profit (TTM)
−$10.71M
Net income (TTM)
−$13.26M
Trailing 12 months
Diluted EPS (TTM)
$0.07
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.85
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.06

Growth

11 metrics
Revenue growth YoY
-96.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.03M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+464.6%
Year over year · more shares
Revenue CAGR (3Y)
+8.0%
Revenue CAGR (5Y)
+26.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-714.3%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$10.02M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-4.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7,879
Latest balance sheet
Cash & equivalents
$7,879
Total assets
$1.86M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$246,464
Capital expenditures (TTM)
$15,000
R&D (TTM)
$165,000
SG&A (TTM)
—
Stock compensation (TTM)
$1.16M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
17 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1509957 CUSIP 63108T105 Visit website